Le Lézard
Classified in: Health
Subjects: CCA, FVT

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024


Conference Call and Webcast to Follow

WASHINGTON, April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2024 on Wednesday, May 8, 2024, after the market closes.

Vanda will host a conference call at 4:30 PM ET on Wednesday, May 8, 2024, during which management will discuss the first quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 2594340.

The conference call will be broadcast simultaneously and archived on Vanda's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Wednesday, May 8, 2024, beginning at 8:30 PM ET and will be accessible until Wednesday, May 15, 2024, at 11:59 PM ET. The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers. The passcode number is 2594340.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact: 
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer 
Vanda Pharmaceuticals Inc.
202-734-3400
[email protected] 

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
[email protected]

SOURCE Vanda Pharmaceuticals Inc.


These press releases may also interest you

at 07:10
PureTech Health plc ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted today that its Founded Entity, Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on...

at 07:05
Exscientia plc : Recent advancements in the Company's pipeline, collaborations and operations, as well as financial results for the first quarter 2024, are summarised below. Exscientia will host a conference call Tuesday, May 21 at 1:30 p.m. BST /...

at 07:05
Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the first patient has been dosed in the global Phase 3 RESTORATiVE303 clinical...

at 07:05
Lam Research Corporation today announced that its Board of Directors approved a $10 billion share repurchase authorization and a forward split of its outstanding shares of common stock at a ratio of 10:1. "The share repurchase authorization...

at 07:05
Eir Partners Capital, LLC ("Eir", "Eir Partners" or the "Firm"), a middle market private equity firm focused on healthcare technology and tech-enabled services, today announced the final closing of Eir Partners Investment Program II with $496 million...

at 07:03
Casterra Ag Ltd., an integrated solutions company for growing castor for bio-based industrial applications, such as biofuels & biopolymers and a subsidiary of Evogene Ltd. , announced it has recently signed new...



News published on and distributed by: